Pathogen-reduced cryoprecipitate: Early experiences and inventory management.

Abstract

Background: Room temperature storage of cryoprecipitated antihemophilic factor (CryoAHF) is limited to 6 h. Consequently, this product is stored frozen until requested, necessitating thawing and delaying fibrinogen supplementation. The FDA has approved the use of pathogen-reduced cryoprecipitated fibrinogen complex (PRCFC), which may be stored at room temperature up to 5 days. Opportunities for rapid dispensing of PRCFC and decreasing wastage were identified.

Methods: Our institution implemented PRCFC in January 2022. Two to eight pools (1-4 doses) of PRCFC were maintained thawed at 20°C-24°C for rapid dispensing. A retrospective analysis of the turnaround time (TAT) to prepare and issue CryoAHF versus PRCFC orders was performed for orders between January 2022 and December 2024. Orders exceeding 60 min to issue were excluded from analysis as these reflected non-urgent orders or cryoprecipitate prepared in advance as part of massive transfusion protocols not released until later shipments.

Results: PRCFC was used in 40.3% of cryoprecipitate orders placed. Comparing PRCFC and CryoAHF, TAT reduction was significant for orders placed from the operating room, labor and delivery, and intensive care units, with reductions in time to prepare and issue of up to 50.0% and 47.7%, respectively (p < 0.001; p < 0.001). The longer shelf life of PRCFC led to a 54.2% reduction in cryoprecipitate wastage from 2021 to 2024.

Conclusion: PRCFC is ready to dispense and provides an immediate source of fibrinogen in critically bleeding patients with significant reductions in TAT. There is an added benefit of reduced wastage.